AllianceBernstein’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.51M Buy
299,077
+235,257
+369% +$4.45M ﹤0.01% 1394
2026
Q1
$1.37M Sell
63,820
-44,605
-41% -$863K ﹤0.01% 2197
2025
Q4
$2.33M Buy
108,425
+20,082
+23% +$423K ﹤0.01% 1910
2025
Q3
$1.7M Sell
88,343
-60,066
-40% -$1.07M ﹤0.01% 2094
2025
Q2
$2.54M Buy
148,409
+15,285
+11% +$652K ﹤0.01% 1810
2025
Q1
$8.5M Sell
133,124
-46,784
-26% -$4.92M ﹤0.01% 1240
2024
Q4
$21.9M Sell
179,908
-39,102
-18% -$4.79M 0.01% 870
2024
Q3
$27.4M Buy
219,010
+4,639
+2% +$641K 0.01% 796
2024
Q2
$33.9M Sell
214,371
-103,866
-33% -$13.3M 0.01% 724
2024
Q1
$41.2M Buy
318,237
+62,326
+24% +$7.63M 0.01% 658
2023
Q4
$24.7M Sell
255,911
-217,741
-46% -$20.9M 0.01% 800
2023
Q3
$57.4M Sell
473,652
-27,649
-6% -$3.13M 0.02% 521
2023
Q2
$57.4M Buy
501,301
+11,069
+2% +$1.43M 0.02% 540
2023
Q1
$67.6M Buy
490,232
+381,524
+351% +$49.5M 0.03% 486
2022
Q4
$14.1M Sell
108,708
-30,901
-22% -$3.58M 0.01% 942
2022
Q3
$15.4M Sell
139,609
-80,467
-37% -$8.11M 0.01% 918
2022
Q2
$16.5M Sell
220,076
-34,988
-14% -$2.57M 0.01% 930
2022
Q1
$19.9M Buy
255,064
+149,631
+142% +$11.5M 0.01% 928
2021
Q4
$9.49M Sell
105,433
-34,430
-25% -$2.94M ﹤0.01% 1276
2021
Q3
$12.9M Buy
139,863
+100,935
+259% +$7.77M 0.01% 1113
2021
Q2
$3.03M Sell
38,928
-9,537
-20% -$723K ﹤0.01% 1931
2021
Q1
$3.61M Sell
48,465
-450,906
-90% -$41.6M ﹤0.01% 1757
2020
Q4
$85.1M Buy
499,371
+37,212
+8% +$5.51M 0.04% 426
2020
Q3
$64.9M Sell
462,159
-52,100
-10% -$7.92M 0.03% 470
2020
Q2
$82.5M Buy
514,259
+47,031
+10% +$6.4M 0.05% 373
2020
Q1
$45.7M Buy
467,228
+11,592
+3% +$1.33M 0.03% 471
2019
Q4
$58.8M Sell
455,636
-81,938
-15% -$8.27M 0.03% 507
2019
Q3
$40.5M Buy
537,574
+42,946
+9% +$5.07M 0.03% 586
2019
Q2
$75.2M Sell
494,628
-79,807
-14% -$9.7M 0.05% 405
2019
Q1
$68.5M Sell
574,435
-20,606
-3% -$2.65M 0.04% 425
2018
Q4
$64.9M Buy
595,041
+324,130
+120% +$40.5M 0.05% 379
2018
Q3
$43.8M Sell
270,911
-126,744
-32% -$17.3M 0.03% 572
2018
Q2
$52.6M Buy
397,655
+206,455
+108% +$19.5M 0.04% 490
2018
Q1
$14.2M Buy
191,200
+73,860
+63% +$4.93M 0.01% 861
2017
Q4
$6.53M Sell
117,340
-52,800
-31% -$2.8M ﹤0.01% 1094
2017
Q3
$7.72M Buy
170,140
+51,830
+44% +$2.07M 0.01% 1028
2017
Q2
$3.99M Buy
118,310
+45,860
+63% +$1.49M ﹤0.01% 1339
2017
Q1
$2.15M Hold
72,450
﹤0.01% 1765
2016
Q4
$1.99M Buy
72,450
+9,700
+15% +$390K ﹤0.01% 1850
2016
Q3
$3.85M Sell
62,750
-29,800
-32% -$901K ﹤0.01% 1280
2016
Q2
$1.76M Buy
92,550
+23,500
+34% +$435K ﹤0.01% 1827
2016
Q1
$1.35M Hold
69,050
﹤0.01% 1906
2015
Q4
$2.66M Sell
69,050
-600
-0.9% -$19.5K ﹤0.01% 1411
2015
Q3
$2.24M Buy
69,650
+750
+1% +$25.4K ﹤0.01% 1559
2015
Q2
$2.1M Buy
68,900
+8,700
+14% +$178K ﹤0.01% 1758
2015
Q1
$799K Sell
60,200
-7,100
-11% -$94.6K ﹤0.01% 2300
2014
Q4
$974K Hold
67,300
﹤0.01% 2214
2014
Q3
$1.42M Hold
67,300
﹤0.01% 1966
2014
Q2
$2M Hold
67,300
﹤0.01% 1767
2014
Q1
$1.62M Hold
67,300
﹤0.01% 1864
2013
Q4
$1.37M Hold
67,300
﹤0.01% 1972
2013
Q3
$3.18M Sell
67,300
-212,502
-76% -$8.18M ﹤0.01% 1359
2013
Q2
$10.6M Buy
+279,802
New +$10M 0.01% 785

Other funds holding SRPT

AllianceBernstein's SRPT Position: Q2 2026 in Review

AllianceBernstein increased its Sarepta Therapeutics (SRPT) stake by 369% in Q2 2026, buying an estimated $4.45M and bringing the position to 299,077 shares worth $6.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1394.

AllianceBernstein first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $85.1M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • AllianceBernstein held 299,077 shares of Sarepta Therapeutics worth $6.51M as of Q2 2026.
  • AllianceBernstein bought 235,257 Sarepta Therapeutics shares in Q2 2026, an estimated $4.45M.
  • Sarepta Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1394 holding.
  • AllianceBernstein first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • AllianceBernstein's Sarepta Therapeutics position peaked at $85.1M in Q4 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.